CytoReason has expanded its collaboration with Sanofi in a multi-year deal worth up to $16 million, deepening the use of AI in drug R&D.
CytoReason, an AI-driven disease modeling company, has expanded its collaboration with Sanofi for the third time, extending a multi-year partnership valued at up to $16 million.
The agreement deepens Sanofi’s use of CytoReason’s technology, which is designed to help researchers extract mechanistic insights from complex molecular and clinical data. The platform enables R&D teams to analyze disease biology and drug effects at scale, supporting faster and more confident decision-making throughout the drug development process.
CytoReason positions itself as a technology company rather than a traditional biotech firm, focusing its investments on building AI infrastructure rather than developing its own drug pipeline. “We made a rare choice in this industry: to be a tech company, not a biotech company,” said Yehuda Chowers, the company’s chief medical officer. He said the platform is now being used by multiple leading pharmaceutical companies to translate data into insights that can influence patient outcomes.
At the core of CytoReason’s approach is an evidence graph trained on hundreds of thousands of data points, enabling scientists to explore disease mechanisms across genes, pathways, cell types, and clinical features in different patient subpopulations. The models are designed to provide a coherent, mechanistic view of how diseases progress and how therapies may intervene.
The company’s scientific research framework incorporates the types of questions drug developers routinely ask of their data, drawing on insights from more than a hundred drug development programs CytoReason has analyzed over the years. The framework continues to evolve as new therapeutic modalities and development strategies emerge.
Also Read: Why Seasonal Hiring Puts Data Security at Risk
CytoReason says its technology helps generate scientific narratives and supports critical inflection points in drug development, allowing teams to move more quickly while maintaining rigor. The expanded collaboration will give Sanofi broader access to the platform’s latest advances in computation and modeling.
“We’re honored to scale our collaboration with immunology powerhouse Sanofi,” said Nicole van Poppel, the company’s chief business officer. She said the next phase of the partnership will help Sanofi scientists inform decisions at speed and increase the impact of their research.
The expanded agreement underscores a growing trend in biopharmaceutical research toward AI-driven platforms that aim to reduce uncertainty and accelerate discovery in an increasingly complex data landscape.
